Pharmacotherapy is the most common treatment for schizophrenia (SCZ), bipolar disorder
(BD), and major depressive disorder (MDD). Pharmacogenetic studies have achieved …

So far, genetic studies of treatment response in schizophrenia, bipolar disorder, and major
depression have returned results with limited clinical utility. A gene× environment interplay …

Antidepressant medications are the most common treatment for major depression and
related disorders. Pharmacogenetic studies have demonstrated that response to these …

DNA methylation is a broadly-investigated epigenetic modification that has been considered
as a heritable and reversible change. Previous findings have indicated that DNA methylation …

Aim: In view of the potential effects of psychiatric drugs on DNA methylation, we investigated
whether medication use in bipolar disorder is associated with DNA methylation signatures …

Major depressive disorder (MDD) is the leading cause of disability worldwide and is
associated with high rates of suicide and medical comorbidities. Current antidepressant …

Bipolar disorder (BD) is a severe mental disorder characterized by repeated mood swings.
Although genetic factors are collectively associated with the etiology of BD, the underlying …

Epigenetic mechanisms such as DNA methylation (DNAm) have been associated with stress
responses and increased vulnerability to depression. Abnormal DNAm is observed in …

The pharmacoepigenetics of antipsychotic treatment in severe mental illness is a growing
area of research that aims to understand the interface between antipsychotic treatment and …

Aim: To identify the DNA methylation status of related genes in major depressive disorder
following selective serotonin-reuptake inhibitor treatment. Materials & methods: 45 patients …